{
  "docId": "019de074-1317-767b-825b-77b5f795fc6c",
  "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 44,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Study 0169 data showing significant increases in Norepinephrine and decreases in DHPG across three patient cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/13",
  "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
  "deckJsonHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c.json",
  "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "chart",
      "text": "MSA, PD, and PAF patient response charts",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2ebbaf9-43ca-4e10-874a-4ee8815804ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.92,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "DHPG, 3,4-dihydroxyphenylglycol; MSA, multiple system atrophy; NE, norepinephrine; PAF, pure autonomic failure; PD, Parkinson's disease; SE, standard error.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42778c82-320e-468a-be31-3d46d6e68bc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*P<0.05. Measurements assessed after 4 weeks of randomized treatment in Study 0169.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd3154ef-e20a-4727-b571-bbb07308eeae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.82
      },
      "kind": "legend",
      "text": "Norepinephrine (blue), DHPG (green)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f4efbd7-7807-4d64-ba7e-b597bed76320",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Greatest Improvements in Plasma NE Were Seen in Patients With MSA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4559a116-f986-4349-a413-2077ce7381a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 13,
      "from": 12,
      "beatId": "7a988e2a-a157-4ca0-ae80-d16ea9c4bca8",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "The deck summarizes key takeaways on ampreloxetine's benefits in MSA patients.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 13,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "1d1e1156-9f19-4a7c-a60c-f5d290947ba3",
      "evidence": "The deck presents data on the greatest improvements in plasma NE levels in patients with MSA.",
      "position": 0,
      "objective": "What are the key benefits of ampreloxetine in MSA patients?",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}